Novo Nordisk to Roll Out Oral Ozempic for Diabetes in Q2, Expanding Blockbuster Drug's Reach
Novo Nordisk announced Wednesday the upcoming U.S. launch of its oral semaglutide tablets under the Ozempic brand, with FDA approval secured for multiple doses. The move marks a significant shift for the popular diabetes treatment from injection to pill form.